Search research articles
Contact Us
Filters
Showing results (1-10 of 85) with videos related to
Page
of 9
Sort By:
Current Oncology (Toronto, Ont.)
|
October 1, 2010
Multimodal approaches to high-risk prostate cancer
A Koupparis, M E Gleave
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates IGF-1 and accelerates androgen-independent progression in prostate cancer
M E Gleave, H Miyake
Cancer Research
|
November 4, 2000
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells
M D Sadar, M E Gleave
Cancer Research
|
June 13, 2000
Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models
H Miyake, M Pollak, M E Gleave
Journal of the National Cancer Institute
|
January 6, 2000
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
H Miayake, A Tolcher, M E Gleave
Cancer Research
|
August 27, 1999
Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
H Miyake, A Tolcher, M E Gleave
International Journal of Cancer
|
June 8, 2000
Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model
H Miyake, B P Monia, M E Gleave
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2000
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
H Miyake, K N Chi, M E Gleave
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2001
Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model
H Miyake, I Hara, S Kamidono, et al.
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls
M E Gleave, S La Bianca, S L Goldenberg
Page
of 9
Search research articles
Search
Showing results (1-10 of 85) with videos related to
Sort By:
Page
of 9
Current Oncology (Toronto, Ont.)
|
October 1, 2010
Multimodal approaches to high-risk prostate cancer
A Koupparis, M E Gleave
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Castration-induced upregulation of insulin-like growth factor binding protein-5 potentiates IGF-1 and accelerates androgen-independent progression in prostate cancer
M E Gleave, H Miyake
Cancer Research
|
November 4, 2000
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells
M D Sadar, M E Gleave
Cancer Research
|
June 13, 2000
Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models
H Miyake, M Pollak, M E Gleave
Journal of the National Cancer Institute
|
January 6, 2000
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
H Miayake, A Tolcher, M E Gleave
Cancer Research
|
August 27, 1999
Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
H Miyake, A Tolcher, M E Gleave
International Journal of Cancer
|
June 8, 2000
Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model
H Miyake, B P Monia, M E Gleave
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2000
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
H Miyake, K N Chi, M E Gleave
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 26, 2001
Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model
H Miyake, I Hara, S Kamidono, et al.
Prostate Cancer and Prostatic Diseases
|
December 24, 2002
Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls
M E Gleave, S La Bianca, S L Goldenberg
Page
of 9